Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer

Summary

The NEOBIL study aims to investigate the feasibility, safety and efficacy of neoadjuvant Bintrafusp alfa in patients with resectable biliary tract cancer.

Timeline

Start

2021-07-08

Primary completion

2021-10-04

Completion

2022-01-05

Outcome

Outcome not reported

Stopped (Enrollment): “Based on results of another phase II study with bintrafusp alfa in combination with gemcitabine plus cisplatin, that was discontinued as it was unlikely to meet the primary endpoint of OS, the recruitment for this study was stopped prematurely.”

Drugs

Indications